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Abstract
Protein folding is the primary role of proteostasis network (PN) where chaperone interactions with client proteins determine
the success or failure of the folding reaction in the cell. We now address how the Phe508 deletion in the NBD1 domain of
the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein responsible for cystic fibrosis (CF) impacts the
binding of CFTR with cellular chaperones. We applied single ion reaction monitoring mass spectrometry (SRM-MS) to
quantitatively characterize the stoichiometry of the heat shock proteins (Hsps) in CFTR folding intermediates in vivo and
mapped the sites of interaction of the NBD1 domain of CFTR with Hsp90 in vitro. Unlike folding of WT-CFTR, we now
demonstrate the presence of DF508-CFTR in a stalled folding intermediate in stoichiometric association with the core Hsps
40, 70 and 90, referred to as a ‘chaperone trap’. Culturing cells at 30 C resulted in correction of DF508-CFTR trafficking and
function, restoring the sub-stoichiometric association of core Hsps observed for WT-CFTR. These results support the
interpretation that DF508-CFTR is restricted to a chaperone-bound folding intermediate, a state that may contribute to its
loss of trafficking and increased targeting for degradation. We propose that stalled folding intermediates could define a
critical proteostasis pathway branch-point(s) responsible for the loss of function in misfolding diseases as observed in CF.
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Introduction
The proteostasis network (PN) is composed of numerous
components that direct the highly variable and adaptable folding
and degradative capacity of the cell [1–3]. This system includes the
stress-inducible heat shock proteins (Hsps) such as the Hsp40,
Hsc70/Hsp70 (Hsc/p70) and Hsp90 chaperone/co-chaperone
ATPase systems [4–10], and the ubiquitin/proteasome degrada-
tion system [2,11–14]. While much progress is being made in
understanding the role of individual components of the PN in
facilitating protein folding, our appreciation of the general
operating principles by which these components cooperate, and
respond to stress and human disease remains largely unknown.
Misfolding diseases such as cystic fibrosis (CF) arise due to the
inability of an altered polypeptide chain sequence to properly
engage key PN components, resulting in reduced folding efficiency
of mutant proteins [1,12,15,16]. The occurrence of CF disease in
the human population is largely caused by deletion of Phe508
(F508) in the cystic fibrosis transmembrane conductance regulator
(CFTR) protein (DF508-CFTR or DF508), leading to its retention
in the endoplasmic reticulum (ER) and subsequent degradation by
ER-associated degradation (ERAD) [3,17–19]. CFTR is a cAMP-
activated chloride channel comprised of two transmembrane
domains (TMD) each containing 6 membrane-spanning helices,
two cytoplasmic-oriented nucleotide-binding domains (NBDs 1
and 2), and a regulatory domain (R). Substantial evidence
demonstrates that failure to deliver DF508-CFTR to the cell
surface reflects its inability to achieve sufficient thermodynamic
stability of the cytoplasmic oriented NBD1 domain missing the
Phe508 residue [20–32]. This defect limits the ability of additional
domains, including the TMD, to interact with NBD1 to form a
structure recognized by the ER-associated COPII export machin-
ery for delivery to the plasma membrane [3,17–19,33,34]. The
loss of CFTR at the cell surface results in dehydration of the
epithelial lining of the lung and other tissues through a disruption
of Na
+ and Cl
2 balance, triggering the progressive pathology
characteristic of the disease [3,35].
The biogenesis of CFTR is regulated by chaperones in the ER
lumen [36] and by the cytosolic Hsp70, Hsp90 and their
regulatory co-chaperones [3,17–19,33,37]. Whereas CFTR fold-
ing is dependent on the Hsp90 system [33,38,39], its targeting for
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chaperone system and the proteasome degradation machinery
[40–43]. Despite a number of studies that have characterized the
role(s) of PN components in the biogenesis of both WT- and
DF508-CFTR, the binding site for these chaperones and the
stoichiometry(s) of potential intermediate folding complexes
contributing to disease remain unknown. A quantitative under-
standing of the composition of folding intermediates and how they
differ between WT and mutant proteins, such as DF508 CFTR, is
critical to begin to understand the principles governing protein-
folding networks in the cell, insights that will improve our ability to
correct misfolding diseases.
Using single ion reaction monitoring mass spectrometry (SRM-
MS) [44,45], we now show that deletion of F508 in CFTR leads to
its accumulation in a folding intermediate complex containing
stoichiometric to supra-stoichiometric ratios of Hsp70 and Hsp90
core chaperones. We further show a differential interaction of
Hsp90 with the WT- and D508-NBD1 in vitro that may contribute
to differences in the interaction of the Hsp90 system with WT and
DF508-CFTR in vivo. Our combined results address a major
question in the chaperone field as to how Hsp90 physically
interacts with client proteins involved in human disease in the WT
and mutant states. They further provide insights into the
mechanisms by which an ER-localized DF508-CFTR folding
intermediate(s) may contribute to CF disease. We suggest that
therapeutic interventions that alter either the composition or
function of the PN may improve the stability of the misfolded
protein allowing it to progress beyond the stalled folding
intermediate(s), and potentially have a major impact on the
treatment of this human disease.
Results
Validation of SRM-MS as a quantitative tool
The biogenesis of both WT- and DF508-CFTR are now
recognized, at least qualitatively, to be dependent on the
functional cycles of Hsp70 and 90 core chaperone systems, despite
a clear difference in their respective trafficking abilities [33,39–43].
Therefore, DF508-CFTR provides a unique opportunity to
quantitatively determine the properties of folding intermediate(s)
that impact disease etiology. Such intermediates are likely to have
been missed in the analysis of the wild-type (WT) protein given its
rapid progress through these early folding intermediates en route
to the functional protein.
In order to understand CFTR folding by the PN components
differentially associated with WT- and DF508-CFTR [33], we
used
15N-labeled protein standards expressed in E. coli and SRM-
MS to provide a quantitative analysis of the complexes generated
during CFTR biogenesis (Fig. 1 & Fig. S1). Intact
15N-labeled
proteins allows for the precise characterization of the digestion and
processing conditions of the endogenous protein for mass
spectrometry. Additionally, SRM-MS allows for analysis of native
and internal standard peptides in rapid succession [46]. Using this
method, parent masses are selected for MS/MS fragmentation
producing unique fragment ions, which are monitored and
quantified in the midst of complex mixtures.
Initial validation was performed in order to compare
15N-
labeled protein based approaches to existing absolute quantifica-
tion strategies based on AQUA synthetic peptides [47]. Fully
labeled chaperone protein standards and labeled synthetic AQUA
peptides from Hsc70 or Hsp90 were independently added to 50 mg
of HEK293 lysate and traced by SRM-MS under identical
chromatographic conditions. The protein abundance of both
chaperones determined using
15N-labeled proteins was compared
to AQUA synthetic peptide standards or quantitative Western
blotting (Fig. 1). All three methods correlated well with
13.662.9 ng/ml of Hsp90 measured using
15N-labeled protein
standard (Fig. 1A & Fig S1A), 19.565 ng/ml using the AQUA
synthetic peptide (Fig. 1A) and 11.060.8 ng/ml using Western
blotting (Fig. 1A). A similar correlation was seen for Hsc70
(Fig. 1B & Fig S1B). The abundance of Hsp90 was determined
to be ,1% of total lysate whereas the abundance of Hsc70 was
estimated at ,0.7% of total lysate. The concordance of these
values with previous studies suggests a high accuracy in abundance
estimation using the
15N-labeled SRM-MS approach.
DF508-CFTR is recovered in a chaperone bound
intermediate in the ER
Transport of CFTR from the ER to the cell surface results in its
processing from the band B glycoform, containing two high
mannose N-linked oligosaccharides to the band C glycoform,
containing Golgi modified glycans that have a slower migration on
SDS-PAGE (Fig. 2B). Immunoblot analysis revealed that WT-
CFTR accumulates in the band C glycoform at a level that is ,10-
times greater than the ER-associated band B pool (Fig. 2B).
However, a similar level of band B is observed in HEK293 cells
expressing either WT- or DF508-CFTR (Fig. 2B). Given that the
rate of nascent synthesis of the two proteins has been shown to be
identical [48], these results suggest that the folding machinery
supporting the availability of band B is similar for WT and DF508.
The WT pool proceeds to the COPII export pathway while
DF508 to degradation. This bifurcation in trafficking decisions is
likely a critical event in the disease etiology associated with CF and
needs to be understood.
To rigorously quantify the levels of chaperones associated with
CFTR at physiological temperature, we first measured the
absolute levels, expressed in pmol, of CFTR, Hsc70 and Hsp90
recovered by CFTR immunoprecipitations from HEK293 cell
lysates expressing either WT- or DF508-CFTR. The complexes
Figure 1. Quantification of CFTR, Hsc70 and Hsp90 in CFTR-
containing complexes. A. Absolute abundance (ng/ml) of Hsp90
calculated by
15N protein labeling, AQUA labeling and Western blotting
(WB). B. Absolute abundance (ng/ml) of Hsc70 calculated by
15N protein
labeling, AQUA labeling and Western blotting (WB). In all panels, data is
shown as mean 6 SD, n$3.
doi:10.1371/journal.pone.0037682.g001
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(NSILNPINSIR(
13C
15N) and GQLLAVAGSTGAGK(
13C
15N)),
to monitor CFTR concentration and
15N-labeled Hsc70 and
Hsp90 before digestion. Using SRM-MS we detected a 12-fold
increase in the molar amount of total WT-CFTR in the
immunoprecipitates as compared to DF508-CFTR, reflecting the
increased stability of the WT protein (Fig. 2A & Table 1),
consistent with the protein levels seen by immunoblotting
(Fig. 2B). A comparison of the recovered molar levels of Hsc70
and Hsp90 between WT- and DF508-CFTR immunoprecipitates
reveals a 1.8-fold increase in Hsp90 from DF508 immunoprecip-
itates, compared to WT, and a modest change in Hsc70 (Fig. 2A
& Table 1). When the absolute molar amounts of recovered
chaperones were normalized to the molar recovery of total CFTR
in each sample (Fig. 2A), it became apparent that DF508-CFTR
complexes contain substantially more bound chaperone. A more
detailed analysis of the DF508 containing band B complexes
reveals a stoichiometric to supra-stoichiometric association of
chaperones at a molar ratio of 1: 2.461.0: 2.261.0 (total CFTR:
Hsp90: Hsc70) (Table 1). In contrast, chaperone recovery with
the total pool of WT-CFTR complexes (band B plus C) is sub-
stoichiometric, exhibiting a molar ratio of 1: 0.160.01: 0.260.01
(total CFTR: Hsp90: Hsc70) (Table 1) illustrating that WT
CFTR is able to mature past the Hsp-bound intermediate. Our
observations using SRM-MS are in agreement with the increased
recovery of Hsp90, Hsc/p70 and Hsp40 seen by immunoblot
analysis of co-immunoprecipitations of both WT- and DF508-
CFTR (Fig. 2B). Furthermore, since these core chaperones do not
stably associate with cell-surface localized WT-CFTR [36], the
results suggest that the ,10% of WT-CFTR recovered in the
band B glycoform is responsible for the observed chaperone
recovery. Therefore, if the molar recovery of chaperones in WT-
CFTR complexes is normalized to the band B recovery in the
immunoprecipitation, we observe a molar ratio of 1: 1.060.3:
1.860.4 (band B CFTR: Hsp90: Hsp70), resembling the molar
ratio seen for DF508-CFTR/chaperone complexes. Given this
observation, we conclude that WT-CFTR may also transit
through a stoichiometric to supra-stoichiometric Hsp-containing
complex prior to ER export. From this perspective, one possibility
is that DF508-CFTR may be trapped in an on-pathway, stalled
folding intermediate rather then an off-pathway, non-productive
intermediate. The stalled Hsp–bound folding intermediate may
explain the enhanced degradation of DF508 observed in vivo and its
failure to be exported from the ER [17–19].
Resolving the Hsp-bound stalled folding intermediate by
reduced temperature
The DF508-CFTR mutant is a temperature-sensitive variant
[49] that achieves productive trafficking and function when cells
are transferred to a permissive temperature (30uC), a condition
known to stabilize the fold [26] and reduce Hsc/p70-dependent
ERAD [36,40,43,50,51]. Since the mechanism by which reduced
temperature achieves stabilization and transport is unknown, we
explored the effect of reduced temperature on the stoichiometry of
DF508-CFTR intermediates characterized above. In order to
eliminate the possibility that degradation is the rate-limiting step,
we examined the effect of the proteasomal inhibitor MG132 on
DF508-CFTR export. While MG132 prevented CFTR degrada-
tion at 37uC, as reported previously [38,52], it did not result in an
increase in trafficking, determined by the ratio of band C to band
B (C/B), a putative measure of export efficiency from the ER
(Fig. S2). Thus, CFTR trafficking out of the ER is not limited by
the availability of the nascent protein.
To clarify when DF508-CFTR can be recovered in an export
competent state, we next examined the effect of the protein
synthesis inhibitor, cycloheximide (CHX), on cells incubated at
37uC and 30uC. At 37uC, we found that DF508 failed to exit the
ER independent of the treatment condition with a substantial
time-dependent loss of CFTR in the presence of CHX (Fig. 3A).
At 30uC, while DF508 was efficiently exported from the ER in the
absence of CHX, no maturation of the DF508 pool synthesized at
37uC, was detected when cells were shifted to 30uC in the presence
of CHX (Fig. 3A). As a control, we did not observe any effect of
CHX on the transport of the WT vesicular stomatitis virus
glycoprotein (VSV-G) over the same time frame (data not shown).
Because VSV-G and CFTR utilize the same exit signals to engage
the COPII ER export machinery [34,53,54], it is unlikely that
CHX interferes with the normal operation of the exocytic
pathway. These data support the interpretation that synthesis of
DF508 at physiological temperature (37uC) generates a folding
intermediate that is irreversibly targeted for degradation (Fig. 2)
and only the pool of DF508-CFTR synthesized and folded at the
permissive temperature is able to be exported.
To address the impact of reduced temperature on the folding of
nascent DF508-CFTR, we examined the interaction of chaperones
with DF508 following a 16 h shift to 30uC, a time period sufficient
to re-establish the steady-state distribution of CFTR in the
exocytic pathway [50] (Fig. 3C). Consistent with the above data
(Fig. 2), DF508-CFTR was recovered in stoichiometric to supra-
stoichiometric association with Hsps at 37uC, exhibiting a molar
ratio of 1: 3.360.9: 3.060.8: 2.060.2 (total CFTR: Hsp90:
Hsc70: Hsp40) (Table 2). Following temperature-shift, CFTR
levels increased 9-fold with .60% of the total DF508-CFTR pool
Figure 2. Quantification of WT and DF508 CFTR interactions
with core chaperones. A. The absolute levels of CFTR, Hsp90 and
Hsc70, expressed in pmol, in CFTR-containing complexes were
determined using the absolute quantification strategy from HEK293
DF508-CFTR (white) and WT-CFTR (black) producing cells. B. Immuno-
blot and densitometric analysis for CFTR, Hsp90, Hsc/p70 and Hsp40
from CFTR-containing immunoprecipitates. A representative blot is
shown. In the densitometric analysis, the relative protein amount is
shown in arbitrary units (a.u.). In all panels, data is shown as mean 6 SD,
n=3 and asterisks represent p value ,0.05 as determined by two-tailed
t-test using the WT sample as the reference.
doi:10.1371/journal.pone.0037682.g002
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was recovered in band B (Fig. 3C). An analysis of DF508-CFTR
complexes at both temperatures reveals a 2-fold decrease in the
molar recovery of all chaperones at 30uC relative to 37uC( Fig. 3B
& Table 2). When the absolute molar recovery of chaperones
seen at 30uC was normalized to total CFTR pool, we obtained a
molar ration of 1: 0.260.04: 0.260.04: 0.160.03 (total CFTR:
Hsp90: Hsc70: Hsp40) (Table 2), similar to the substoichiometric
ratio we determined for the total pool of WT-CFTR (Table 1).
These observations are again supported by immunoblotting
analyses, where the level of chaperones recovered with DF508-
CFTR at 37uC, were reduced following low temperature rescue
(Fig. 3C). An analysis of the stoichiometry of DF508-CFTR
complexes still localized in the ER (band B) reveal a sub-
stoichiometric association of chaperones with a ratio of 1: 0.460.1:
0.560.1: 0.260.1. Furthermore, an analysis of Hsp90 recovery
with DF508-CFTR by SRM-MS after a 30 min and 6 h
temperature rescue revealed a progressive shift from a stoichio-
metric recovery to a sub-stoichiometric recovery (data not shown).
These data suggests that the low temperature rescue of DF508-
CFTR alters the stoichiometric association of chaperones with the
mutant in a manner similar to what is seen with WT-CFTR.
These changes may, in part, reflect the slower folding and
trafficking kinetics of ER export at 30uC due to energetic
stabilization of the DF508 fold at reduced temperature (restoring
WT-like interactions with PN components), and/or by changes to
the PN composition or its function that may occur in response to
incubation of cells at reduced temperature.
Differential recognition of WT- and DF508-NBD1 by the
Hsp90
In order to shed light on the differential ability of WT- and
DF508-CFTR to resolve the Hsp-bound intermediate in the ER at
physiological temperature, we examined their interactions in vitro.
Purified Hsp90ß was incubated with either purified recombinant
WT- or DF508-NBD1 in the presence of ATP. A zero-length
cross-linker was used to capture the interactions and mass
spectrometry was used to map the cross-linked peptides, using
our recently described approach for defining the interaction of
Hsp90 with its co-chaperone Aha1 [39]. Both DF508- and WT-
NBD1 interacted with Hsp90 via a common binding site spanning
the helix 8-helix 9 (H8–H9) region located at the C-terminus of the
NBD1 domain (residues 624–643) (Fig. 4A (peptide 5), Fig. 4B,
C & Fig. S3). This common binding site represented the only
interaction site between Hsp90 and DF508-NBD1, whereas WT-
NBD1 exhibited four additional Hsp90 binding sites (Fig 4A, C &
Fig S3). Three of these additional sites, as well as the H8–H9
binding site, locate to the NBD1-NBD2 dimerization interface,
which includes the Walker A motif region (residues 453–464),
which is critical for ATP binding and formation of a stable NBD1-
NBD2 dimer (Fig. 4A (peptide 2), Fig. 4C & Fig. S3). The last
unique site of Hsp90 binding to WT-NBD1 is located on the
opposite face of the domain, in close proximity to the F508 residue
(residues 526–532) (Fig. 4A (peptide 4), Fig. 4C & Fig. S3). Gel
filtration chromatography did not reveal aggregation of the
DF508-NBD1 domain (data not shown), suggesting that the
reduced number of interaction sites with Hsp90 seen with the
mutant NBD1 are not due to a lower availability of this protein.
This in vitro data highlights the impact of the DF508 mutation on
the folding of NBD1, suggesting that the structural differences
between the WT and DF508-NBD1 impede the ability of the
mutant variant to properly engage the Hsp90 chaperone system.
Table 1. Stoichiometry of the WT and DF508 CFTR interaction with core chaperones.
DF508
Molar Ratio to Total
CFTR WT
Molar Ratio to Total
CFTR Fold Change
CFTR 2.961.2 pmol 1.0 35.661.7 pmol 1.0 +12.365.1
Hsp90 6.461.2 pmol 2.461.0 3.561.0 pmol 0.160.01 21.860.3
Hsp70 7.160.2 pmol 2.261.0 6.660.1 pmol 0.260.01 21.160.03
Table depicting the absolute amounts of CFTR, Hsp90 and Hsc70, expressed in pmol. Also shown are the molar ratios of chaperones to total DF508- or WT-CFTR. The
fold change in the absolute amounts of CFTR, Hsp90 and Hsc70, expressed in pmol, relative to DF508-CFTR is shown in the final column.
doi:10.1371/journal.pone.0037682.t001
Figure 3. Quantification of DF508-CFTR interaction with core
chaperones following temperature shift. A. Western blot analysis
of HEK293 cells stably expressing DF508-CFTR cultured at 37uCo r3 0 uC
in the presence of 50 mM cyclohexamide (CHX) or vehicle control for the
indicated time. B. Absolute quantification of DF508 CFTR and
interacting chaperones at 37uC (black) or 30uC for 16 h (white).
Absolute protein abundance of CFTR, Hsp90, Hsc70, and Hsp40 in
CFTR-containing complexes is shown and expressed in pmols. C.
Immunoblot and densitometric analysis for CFTR, Hsp90, Hsc/p70 and
Hsp40 in CFTR-containing immunoprecipitates. In the densitometric
analysis, the relative protein amount is shown in arbitrary units (a.u.). In
all panels, data is shown as mean 6 SD, n=3 and asterisks represent p
value ,0.05 as determined by two-tailed t-test using the DF508-CFTR at
37uC sample as the reference.
doi:10.1371/journal.pone.0037682.g003
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DF508-NBD1 interacted with the N-terminal domain of Hsp90
(Fig. 4D & Fig. S3), WT-NBD1 also interacted with the middle
domains of Hsp90 via the additional NBD1 interaction sites
(Fig. 4E & Fig. S3). Since both regions of Hsp90 have previously
been implicated in client interactions [4], these data show that
Hsp90 may require the additional contact sites found in WT-
NBD1 to properly engage this client in order to complete the
folding cycle, a step that is impaired in the absence of F508. We
suggest that the inability of DF508 to properly integrate with the
Hsp90 chaperone machinery to complete its folding cycle and
trigger chaperone release is a major contributing factor to the
inefficient ER export of DF508 by COPII and contributes to its
efficient targeting for ERAD.
Discussion
Although Hsp90 has previously been shown to qualitatively
participate in the biogenesis of CFTR [33,38,39], a quantitative
description of how the WT and mutant CFTR engage the PN in
health and disease has been elusive. To address this concern, we
have focused our attention on the role of the PN in managing the
DF508 mutant fold. Using quantitative SRM-MS, we have now
characterized a novel folding step(s) that occurs as a result of the
altered ability of DF508-CFTR to interact with PN components
critical for its biogenesis. We observed that the DF508 mutant
accumulates in vivo in a stalled folding intermediate(s) containing
stoichiometric to supra-stoichiometric core components of the Hsp
folding system. Previous analyses of purified NBD1 and full length
CFTR have revealed structural defects associated with the F508
deletion [25,31,48,55]. We have now demonstrated the conse-
quence of these structural differences in vitro- an altered recognition
by Hsp90 of WT and mutant NBD1. Together, our in vivo and in
vitro analyses provide new insights into the key role of chaperones
in CFTR WT and disease biology, and highlights the importance
of quantitatively characterizing folding intermediates using SRM-
MS technologies in order to understand the role of the PN in
human misfolding disease.
Our finding reveal that the deletion of F508 alters the ability of
the NBD1 to interact with Hsp90 in vitro provides new insight into
possible steps that contribute to disease. We found that the H8–H9
region of NBD1 is the only common site of Hsp90 recognition
between WT NBD1 and DF508 NBD1. In contrast, Hsp90
interacted with WT-NBD1 through 4 additional binding sites that
localize to the NBD2 dimerization interface and the a-helical
domain of NBD1. Specifically, the middle domain of Hsp90 binds
to peptide 4, which localizes to the recently identified folded core
of NBD1 [20], a region thought to be critical for the stability and
subsequent folding of WT-CFTR [20,21,23,25,26,28–30,56]. This
stable core structure is never achieved in DF508-NBD1, unless the
I539T and/or other suppressor mutations are introduced
[20,21,23,29,30]. Interestingly, peptide 4 spans residues 525–532
of NBD1, which places it in close proximity to the I539T mutation
and within the stable core of the WT protein. While the binding
interactions observed with Hsp90 in vitro used purified, recombi-
nant NBD1, previous evidence strongly suggests the importance of
Hsp90 for CFTR function in vivo [33,38,39]. We now raise the
possibility that the inability of DF508-NBD1 to achieve its native
Table 2. Stoichiometry of the DF508 CFTR interaction with core chaperones at physiological and corrective temperatures.
DF508 (376C)
Molar Ratio to Total
CFTR DF508 (30
oC)
Molar Ratio to Total
CFTR Fold Change
CFTR 1.160.1 pmol 1.0 10.261.7 pmol 1.0 +9.361.7
Hsp90 3.661.0 pmol 3.360.9 1.760.3 pmol 0.260.04 22.160.7
Hsp70 3.360.8 pmol 3.060.8 1.960.3 pmol 0.260.04 21.760.5
Hsp40 2.260.1 pmol 2.060.2 0.860.3 pmol 0.160.03 22.861.0
Table depicting the absolute amounts of CFTR, Hsp90, Hsc70 and Hsp40, expressed in pmol. Also shown are the molar ratios of chaperones to total DF508-CFTR at both
37uC and 30uC. The fold change in the absolute amounts of CFTR, Hsp90 and Hsc70, expressed in pmol, relative to DF508-CFTR at 37uC is shown in the final column.
doi:10.1371/journal.pone.0037682.t002
Figure 4. Structural mapping of the Interaction of NBD1 with
Hsp90 using cross-linking. A. Ribbon diagram of NBD1 depicting
Hsp90 interacting peptides. B–C Ribbon diagram of DF508-NBD1 (B)
and WT-NBD1 (C) with associated Hsp90 interacting peptides shown as
electrostatic map. D–E. Ribbon diagram of Hsp90 with associated
DF508-NBD1 (D) and WT-NBD1 (E) interacting peptides shown as
electrostatic map. Data shown is conserved peptides from 3 indepen-
dent experiments.
doi:10.1371/journal.pone.0037682.g004
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vitro. This altered recognition could favor targeting of DF508
CFTR for degradation and/or prevent trafficking of DF508-
CFTR from the ER.
In addition to characterizing the differential binding of Hsp90
to WT- and DF508-NBD1 in vitro, our quantitative SRM-MS
analysis has revealed the stoichiometries of Hsp chaperone
complexes binding full-length CFTR in vivo. The ER localized
DF508-CFTR complexes (band B) at 37uC exhibited chaperone
stoichiometries of 1:2:2 to 1:3:3 (CFTR: Hsp90: Hsc70), suggest-
ing that at least a functional dimer of Hsp90 and several (2–3)
Hsp70 monomers are bound to each molecule of DF508 CFTR.
In contrast, we recovered the total pool of WT CFTR (bands B
plus C) at a chaperone stoichiometry of 1:0.2:0.2 (CFTR: Hsp90:
Hsc70) at 37uC, leading us to suggest that WT CFTR matures
through early chaperone-dependent steps defined by the stoichi-
ometries potentially associated with band B WT CFTR. Thus, we
suggest that DF508 accumulates in a stalled folding intermediate,
the chaperone trap, impeding its progression along the folding and
trafficking axis, resulting in its targeting for degradation. Consis-
tent with this interpretation, our results also directly demonstrate
that reduced temperature rescue of DF508-CFTR in vivo can
resolve this stalled Hsp-bound intermediate, leading to restoration
of the sub-stoichiometric Hsp chaperone association observed for
the WT protein in vivo. One possibility is that reduced temperature
provides thermodynamic stability to the nascent DF508-NBD1
fold, partially restoring folding and, hence, WT-like interactions
with PN components critical to its biogenesis. Alternatively,
reduced temperature may change the composition of the PN and/
or the properties of existing PN components, altering their
interactions with DF508-CFTR and thereby promoting folding
and trafficking. These potential interpretations are consistent with
the effect of siRNA silencing of Aha1 [33], where we found that
altering the ATPase activity of Hsp90 can restore function at the
cell surface. Altering the PN to restore function is consistent with
the observed effects of PN modulating proteostasis regulators,
[2,11,12], on the activity of the UPR [57] and the HSR [58,59]
signaling pathways, that can be used to correct a wide range of
protein folding problems [8,60–76]. Although our studies high-
lighting the interaction of NBD1 with Hsp90 were performed in
vitro with purified proteins, we suggest that the structural
interactions observed in these in vitro experiments are reasonable
candidates for the structural interactions occurring in vivo with full-
length CFTR contributing to the chaperone trap state.
Our studies lead us to propose a minimal sequential ordering of
intra- and inter-domain folding events that manage the biogenesis
of WT-CFTR, which fails in human DF508 disease (Fig. 5). Here,
intra-domain folding of WT NBD1 could involve a stoichiometric
interaction with the Hsc/p70-Hsp90 chaperone system, as shown
herein (Fig. 5, step 1). This is consistent with the many
descriptions of the role of the Hsc/p70-Hsp90 chaperone system
in the nascent protein folding of other proteins
[9,32,33,38,39,64,66,68,77–87]. A recent analysis of the crystal
structure of NBD1 reveals that the H8–H9 helices, recognized by
Hsp90 (Fig. 4), would have to be re-oriented in order to promote
dimerization and post-translational chaperoning of NBD2 [88–
91]. NMR studies have also shown that such a structural
rearrangement occurs in response to the binding of cytoplasmic
loop 4 (CL4), a short loop that links helices 10 and 11 in TMD2
(shown in orange in Fig 5), to the F508 containing hydrophobic
pocket present in WT NBD1 [88–91]. Because NBD1 interacts
with CL4, one possibility is that Hsp90, when properly engaged,
generates a stabilized folding intermediate capable of CL4 binding
(Fig. 5, step 2). Together with the reported effects of the DF508
mutation on interactions with additional TMD loops [89–92], and
the folding and stability of NBD2 [48], the binding of CL4 could,
as suggested by others [89–94], contribute to the subsequent
stabilization of NBD1, potentially resolving the Hsp90 interaction
and promoting H8–H9 helix-coil transition. The release of Hsp90
and the reorientation of the H8–H9 helices would now expose the
NBD2-binding interface of NBD1 allowing for NBD1-mediated
chaperoning of NBD2 (Fig. 5, step 3) [21,29]. Although both WT-
and DF508-NBD1 interact with Hsp90 via the H8–H9 region, we
suggest that DF508 may be unable to achieve the CL4 binding
competent intermediate, possibly due to the inability of the mutant
to properly engage the Hsp chaperone system at the additional
binding sites shown in vitro that includes the stable folded core that
occurs during folding of WT-NBD1 (Fig. 4). This results in
trapping of the DF508-CFTR in the stalled Hsp90-dependent
folding step observed herein. Whether this is an on-pathway or off-
pathway intermediate remains to be shown, particularly given the
complexity of the Hsp90 chaperone system, which could have
different kinetic and/or thermodynamic branch points sensitive to
the progress of the folding reaction. Failure to resolve this Hsp-
bound stalled intermediate would likely interfere with subsequent
inter-molecular interactions, such as NBD2 dimerization and
subsequent folding of full length CFTR (Fig. 5).
While further experiments are required, the stalled folding
intermediate may direct DF508 along an alternative pathway
responsible for degradation by the proteasome [3,17–19] (Fig. 5).
We now suggest that targeting the PN through proteostasis
regulation [2,11,12,33,95] may alter the interaction of DF508-
CFTR with the stalled Hsp90 chaperone system [1,12]. One
possibility is that by managing the activity of the ATPase
regulators of Hsp90 and Hsc/p70 by Aha1 (Hsp90) [33] or
Hsp40 isoforms [37], respectively, we will create a folding
environment that stabilizes DF508-NBD1 of CFTR for subsequent
folding steps involving downstream domains such as NBD2,
thereby enhancing exit from the ER. Alternatively, given that
DF508-CFTR is very often detected in an unstable band C form at
the cell surface, proteostasis regulation could contribute to a new
chaperone environment that stabilizes this cell surface localized
species, enhancing channel function. Thus, by managing the
composition and/or activity of the PN, we may promote both
assembly and stability of CFTR. Proteostasis regulation could have
an important impact on mitigating CF in the clinic.
Materials and Methods
Preparation and purification of
15N-labeled proteins
Human Hsp90b, Hsc70 (heat shock cognate 71 kDa, isoforms 1
and 2), and Hsp40 heat shock 40 kDa (protein 4), were cloned into
pET11d vector containing a hexa-histidine tag. The plasmids were
transformed into E. coli (strain BL21) and grown to an OD
between 0.8–1.0 in .98%
15N-atom Spectra 9 labeling media
(Spectra Stable Isotopes). Protein expression was induced with
1 mM IPTG at 18uC overnight. Cells were harvested and lysed by
sonication. The cleared supernatants were subsequently applied to
a 1 ml HisTrapHP chelating column (GE Healthcare), charged
with nickel sulfate controlled by an AKTA FPLC system (GE
Healthcare) using the following buffer system: IMAC Buffer A
(50 mM KH2PO4 pH 8.0, 500 mM KCl, 5 mM ß-mercaptoeth-
anol; IMAC Buffer B (50 mM KH2PO4 pH 8.0, 500 mM KCl,
1 M Imidazole, 5 mM ß-mercaptoethanol). Bound proteins were
eluted with imidazole and further purified by anion exchange
chromatography on a 1 ml MonoQ HR 5/5 column (GE
Healthcare) using the following buffer system: AE Buffer A
(20 mM Tris pH 7.5, 1 mM Mg-acetate, 1 mM DTT); AE Buffer
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DTT). Hsc70, and Hsp90 were further purified using gel filtration
using a 20 ml Superose 6 HR 10/30 column (GE Healthcare) in
50 mM Hepes pH 7.2, 500 mM NaCl, 1 mM MgCl2, 1 mM
DTT. The purified proteins were then dialyzed against 25 mM
Hepes pH 7.2, 125 mM K-acetate. The resulting proteins were
tested for purity using silver stained gels and mass spectrometry.
The percent atomic enrichment was estimated as previously
described [96–98].
Immunoblotting
A dilution series of
14N recombinant, purified Hsc70 (isoform 1
and 2), Hsp90b and HEK293 lysates were analyzed by Western
immunoblotting with rabbit polyclonal heat shock protein 90
antibody (Stressgen SPA-846) (1.20 000) and rabbit polyclonal
antibody recognizing both Hsp70 and Hsc70 (Stressgen SPA-812)
(1:50,000). Chemiluminescent detection was performed with ECL,
using goat anti-rabbit IgG horse radish peroxidase (1:10,000)
(Pierce). Densitometric analysis was performed using Image J
software.
Sample preparation for validation experiments
Three labeled AQUA peptides for CFTR (ADLINNGTIAK
(
13C
15N), SFYPEEVSSMVLTK (
13C
15N), and GQLLAVST-
GAGK(
13C
15N)) were purchased from Sigma Genosys, and
dissolved in formic acid to a final concentration of 5 pmol/ml.
An aliquot of HEK293 cell lysate (50 mg) was mixed with 2 mgo f
15N labeled Hsp40, Hsc70 and Hsp90 proteins, a second 50 mg
aliquot of HEK293 cell lysate was mixed with 5 pmols/ml of the
labeled AQUA peptides SFYPEEVSSMVLTK (Hsc70) and
ADLINNGTIAK (Hsp90), and a 2 mg aliquot of HEK293 cell
lysate was retained for Western blot analysis. These analyses were
performed in triplicate. For TSQ analysis 5 mg of lysate was mixed
with 0.6 mg and 0.2 mgo f
15N labeled Hsp40, Hsc70 and Hsp90,
respectively. Analysis was also performed in triplicate.
Cell culture
HEK293 cell lines either not expressing or stably expressing
either WT or DF508-CFTR was kindly provided by Dr. Neil A.
Bradbury (University of Pittsburgh School of Medicine, Pitts-
burgh, PA 15261) and grown in DMEM supplemented with 10%
FBS and Pen/Strep plus 150 mg/ml hygromycin B at 37uC.
Temperature shift experiments were performed by placing plates
at 30uC for 16 h.
Anti-CFTR coupling to beads
Monoclonal antibody (M3A7) against an epitope at the C-
terminal end of NBD2 [99] was coupled to Gamma Bind Beads
(Amersham) at final concentration of 4 mg/ml using dimethylpi-
melimidate (Pierce 21667). In brief, 2–4 mg per ml of wet beads
were incubated with the appropriate amount of M3A7 antibody at
room temperature for 1 h with rocking. The beads were washed
once with 10 volumes of 0.1 M sodium borate pH 9 by a brief
centrifugation (30006g for 5 min) and subsequently resuspended
Figure 5. Minimal sequential ordering of intra- and inter-domain folding events responsible for CFTR folding and trafficking. Intra-
domain folding of NBD1 is dictated by the Hsp90 system (step 1). A structural rearrangement occurs in response to the binding of cytoplasmic loop 4
(CL4) to the F508 containing hydrophobic pocket present WT NBD1 (step 2). The binding of CL4 provides a stabilizing effect on NBD1, releasing
Hsp90 and promoting H8–H9 helix-coil transition. This H8–H9 transition would expose the NBD2-binding interface of NBD1 and allow NBD1 to
‘chaperone’ in trans the folding of NBD2 (step 3).
doi:10.1371/journal.pone.0037682.g005
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dimethylpimelimidate (DMP) (Pierce 21667) was added in solid
form to a final concentration of 20 mM and mixed by rocking for
30 min at room temperature. The beads were subsequently
washed once with 0.2 M ethanolamine (pH 8) and remaining free
crosslinker was quenched by incubating the beads for 2 h at room
temperature in 0.2 M ethanolamine. The beads were washed with
three changes of PBS pH 7.4 and resuspended in PBS containing
0.02% sodium azide as a preservative and stored at 4uC.
CFTR Immunoprecipitation
HEK293 cells expressing either WT- or DF508-CFTR were
washed with 2 changes of ice cold PBS, and lysed in the dish on ice
using lysis buffer (25 mM TRIS pH 7.4, 150 mM NaCl, 1%
Triton X 100, protease inhibitor at 2 mg/ml final concentration
(Roche 11836145001)) at 15 ml lysis buffer/cm
2. Cell lysates (1 mg
total protein) were incubated with 60 ml of 50% slurry of M3A7
Sepharose beads overnight at 4uC. The beads were subsequently
washed with 3 changes of 300 ml of wash buffer (50 mM Tris
pH 7.4/150 mM NaCl) and bound protein eluted in elution buffer
(50 mM Tris pH 6.8, 1% SDS). Eluted proteins were either
methanol/chloroform precipitate and subjected to tryptic diges-
tion and mass spectrometric analysis or subject to Western blot
analysis as described above. The analyses comparing WT versus
DF508 and DF508 at 37uCv sDF508 at 30uC are paired and done
separately.
Purification of NBD1
Recombinant human WT- and DF508-NBD1 were a kind gift
from Dr Gergely Lukacs (McGill University, Department of
Physiology, Montreal, Quebec) and were purified as previously
described [100]. The domain includes residues 389–678 for WT-
NBD1 and 389–677 for DF508-NBD1 and contains both the
regulatory insertion (RI) (404–435) and the regulatory extension
(RE) (639–670). The sequences are listed below.
NBD1-WT(F494N)-TTEVVMENVTAFWEEGFGELFE-
KAKQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINF-
KIERGQLLAVAGSTGAGKTSLLMMIMGELEPSEGKIKHS-
GRISFCSQNSWIMPGTIKENIIFGVSYDEYRYRSVIKACQ-
LEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYK-
DADLYLLDSPFGYLDVLTEKEIFESCVCKLMANK-
TRILVTSKMEHLKKADKILILHEGSSYFYGTF-
SELQNLQPDFSSKLMGCDSFDQFSAERRNSILTETLHRF-
SLEGDAPVS.
NBD1-DF508 (F494N)-TTEVVMENVTAFWEEGFGELFE-
KAKQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINF-
KIERGQLLAVAGSTGAGKTSLLMMIMGELEPSEGKIKHS-
GRISFCSQNSWIMPGTIKENIIGVSYDEYRYRSVIKACQ-
LEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYK-
DADLYLLDSPFGYLDVLTEKEIFESCVCKLMANK-
TRILVTSKMEHLKKADKILILHEGSSYFYGTF-
SELQNLQPDFSSKLMGCDSFDQFSAERRNSILTETLHRF-
SLEGDAPVS.
Crosslinking of Hsp90 with NBD1
A mixture of 10 mM purified, recombinant human Hsp90b was
mixed with 10 mM of purified, recombinant human WT-NBD1 or
DF508-NBD1 in 25 mM HEPES, pH 7.4, 100 mM NaCl and
allowed to bind on ice for 30 min. A freshly prepared mixture of
EDC and Sulfa-NHS were added to the protein solution and
incubated for 30 min at room temperature to crosslink the bound
proteins. Excess crosslinker was subsequently quenched by the
addition of Tris-HCl and incubation at room temperature for an
additional 15 min. The proteins were then acetone-precipitated
and trypsin-digested for mass spectrometric (MS) analysis as
described previously [27].
Digestion
The precipitated eluates from above were resuspended in
100 mM Tris pH 8.5 and mixed with 0.3 mg Hsp90, 1 mg Hsp70,
1 mg Hsp40 and 5 pmols CFTR AQUA peptide. The samples
were denatured by addition of solid urea to a final concentration of
8 M. The sample was reduced with 3 mM TCEP (Sigma) for
20 min at room temperature and subsequently alkylated with
10 mM iodoacetamide (Sigma) for 30 min at room temperature.
The samples were then digested overnight with trypsin by adding
1/50 total volume of trypsin solutiion (Prote ´ge ´).
Mass spectrometry
Using multidimensional protein Identification technology
(MudPIT) [55–57] the protein digest was pressure-loaded onto a
fused silica capillary desalting column containing 5 cm of 5 mm
Polaris C18-A material (Metachem, Ventura, CA) packed into a
250-mm i.d capillary with a 2 mm filtered union (UpChurch
Scientific, Oak Harbor, WA). The desalting column was washed
with buffer containing 95% water, 5% acetonitrile, and 0.1%
formic acid. After desalting, a 100-mm i.d capillary with a 5-mm
pulled tip packed with 10 cm 3-mm Aqua C18 material
(Phenomenex, Ventura, CA) followed by 3 cm 5-mm Partisphere
strong cation exchanger (Whatman, Clifton, NJ) was attached to
the filter union and the entire split-column (desalting column–filter
union–analytical column) was placed inline with an Agilent 1100
quaternary HPLC (Palo Alto, CA) and analyzed using a modified
12-step separation described previously [26]. The buffer solutions
used were 5% acetonitrile/0.1% formic acid (buffer A), 80%
acetonitrile/0.1% formic acid (buffer B), and 500 mM ammonium
acetate/5% acetonitrile/0.1% formic acid (buffer C). Step 1
consisted of a 100 min gradient from 0–100% buffer B. Steps 2–
5 had the following profile: 3 min of 100% buffer A, 2 min of X%
buffer C, a 10 min gradient from 0–15% buffer B, and a 97 min
gradient from 15–45% buffer B. The 2 min buffer C percentages
(X) were 15, 30, 40, 60% respectively for the 5-step analysis. The
final step, the gradient contained: 3 min of 100% buffer A, 20 min
of 100% buffer C, a 10 min gradient from 0–15% buffer B, and a
107 min gradient from 15–70% buffer B. As peptides eluted from
the microcapillary column, they were electrosprayed directly into
an LTQ dimensional ion trap mass spectrometer (ThermoFinni-
gan, Palo Alto, CA) with the application of a distal 2.4 kV spray
voltage. Following a cycle of one full-scan mass spectrum (400–
1400 m/z), parent ions were selected for collision at 1.5 m/z
width in data independent mode at 35% normalized collision
energy. This was repeated continuously throughout each step of
the multidimensional separation. The validation experiment
reported in the text of the Results was performed on both LTQ
and a TSQ Quantum Ultra, a triple quadripole instruments to test
the validity of the approach with a resulting high correlation of
absolute measurements. Substantially less starting material and a
shorter separation gradient was used in TSQ analysis, highlighting
its increased sensitivity for this technology.
TSQ reverse phase analysis
In the TSQ Quantum ultra (ThermoElectron, San Jose, CA),
peptides were monitored by single-ion reaction monitoring (SRM)
mass spectrometry (SRM-MS) as described in the Results.
Precursor and fragment ion selection and collision energies were
empirically determined from LTQ data fragmentation data and
TSQ analysis of purified proteins. The digested peptides were
loaded under pressure onto a reverse phase column (100 mm
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TM
MS Pump was used to produce and deliver a solvent gradient (A:
0.1%FA/5%ACN) (B: 0.1%FA/80%%ACN) The flow rate was
200 nL/min with the use of a flow splitter. The linear ramp was
from 15% B to 100% B in 50 min. Quantum Q1 was kept at
0.7 m/z and Q3 at 0.7 m/z with a scan time of 0.1 seconds and
0.02 scan width.
Data analysis
Tandem mass spectra were searched as described [55–57] using
the SEQUEST algorithm against an EBI-IPI human 3.05 04-04-
2007 database concatenated to a decoy database in which the
sequence for each entry in the original database was reversed. The
validity of peptide/spectrum matches was assessed using the
SEQUEST-defined parameters, cross-correlation score (XCorr),
and normalized difference in cross-correlation scores (DeltaCn).
SEQUEST results were assembled and filtered using the
DTASelect (version 2.0) program. DTASelect 2.0 uses a quadratic
discriminant analysis to dynamically set XCorr and DeltaCN
thresholds for the entire data set to achieve a user specified false
positive rate (5% in this analysis). The false positive rates are
estimated by the program by ratioing the number and quality of
spectra to the decoy database. For
15N enrichment calculations a
published algorithm was used, based on information from high-
resolution scans which determined the
15N peptide isotopic
distributions, which are characteristic of the
15N atomic percent
enrichment of the peptide.
Calculation of peptide and protein ratios extraction of
chromatograms
After filtering the results from SEQUEST using DTASelect2
ion chromatograms were generated from tandem mass spectra
using a program CENSUS [101]. This was used to calculate
peptide ion intensity ratios for each pair of extracted ion
chromatograms. Several spectra were manually validated. For
TSQ data peaks area ratios were determined manually in Xcalibur
or using Thermo Finnigan software LC Quant.
Supporting Information
Figure S1 Validation of absolute quantification method
for rescue of CFTR.( A) Absolute abundances of Hsp90
peptides (ng/ml) calculated by SRM-MS: (1) ELISNASDALDK
(2) ELISNANSDALDKIR ((3) ADLINNLGTIAK (4) NPDDIT-
NEEYGEFYK. (B) Absolute abundances of Hsc70 peptides (ng/
ml) calculated by SRM-MS: (1) NQVAMNPTNTVFDAK (2)
SFYPEEVSSMVLTK (3) SQIHDIVLVGGSTR (4) SINPDEA-
VAYGAAVQAAILSGDK. All panels, data is shown as mean 6
SD, n=3.
(TIF)
Figure S2 nF508 fails to exist the ER when bound to
chaperones at physiological temperatures. Western blot
analysis of CFBE cells treated with 50 mM MG132 or vehicle
control for 6 h at 37uC. Data shown is the mean 6 SD, n=3.
(TIF)
Figure S3 Peptides recovered in cross-linking experi-
ments. Consensus peptides recovered in the cross-linking of
Hsp90 with WT- or    F508-NBD1. The color of the respective
peptides is in accordance with the highlighted peptides in Fig. 4A.
The location of these peptides in WT- and DF508-CFTR are
illustrated in the sequence. The corresponding Hsp90 cross-linked
peptide is also indicated in matching color in the included
sequence.
(TIF)
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